Actinium-225 (225 Ac, Ac-225) is an isotope of actinium. It undergoes alpha decay to francium-221 with a half-life of 10 days, and is an intermediate decay product in the neptunium series (the decay chain starting at 237 Np ).

Actinium-225 is potentially more effective than Lutetium-177 because of its alpha radiation, which causes double strand breaks in DNA. At the same time, its radiation is shorter, which determines less toxicity to the bone marrow. The main advantage of Actinium-225 is that it provides a good therapeutic outcome even in patients who have not ...

This work includes the production of a promising new weapon in the fight against cancer—Actinium-225—a radioisotope so rare that the annual global production is less than a grain of sand.

Targeted alpha particle therapy (TAT) has emerged as a promising strategy for the treatment of prostate cancer (PCa). Actinium-225 (225 Ac), a potent alpha-emitting radionuclide, may be incorporated into targeting vectors, causing robust and in …

Actinium-225 is the radioisotope of the element actinium, whose atomic nucleus has 136 neutrons in addition to the element-specific 89 protons, resulting in a mass number of 225. There are approaches for targeted alpha therapy for the treatment of several cancer types where Ac-225 could be used [2].

2018年6月20日 · Although research into promising cancer treatments using actinium-225 started with a rare and limited source, DOE scientists have found a new way to. This picture shows three different images of a single patient with end-stage prostate cancer.

Discovered in 1947 by a team at Argonne National Laboratory and an independent Canadian research team, actinium-225 (Ac-225) undergoes alpha decay to francium-221 with a half-life of 10 days. For this reason, the isotope is being evaluated as …

2024年2月13日 · Researchers have known that actinium 225 would likely be useful for cancer treatment for more than 30 years, beginning with the publication of a paper entitled “The Feasibility of 255...

Actinium-225 and its progeny present unique radiobiological and dosimetric challenges to the medical physicist because of the multiple progeny, the diverse progeny chemical characteristics and pharmacokinetic profiles, and the short-range, high LET α-particle emissions.

2024年1月10日 · Actinium-225 (225 Ac) prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) is a novel therapy for metastatic castration-resistant prostate cancer (mCRPC).